Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 29 11 2019
revised: 04 12 2019
accepted: 06 12 2019
entrez: 2 1 2020
pubmed: 2 1 2020
medline: 11 1 2020
Statut: ppublish

Résumé

Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally advanced tumors (LABC) that aims at achieving a complete pathological response (pCR). Studies have been conducted to evaluate and identify te concordance between radiological, histopathological and biological variables of BC and final response to therapy, verified by definitive histological examination after surgery. Ninety-five BC patients were examined and subjected to NAC. Immunohistochemical markers including oestrogen-receptor (ER), progesterone-receptor (PR), Ki67 index, and human epidermal growth factor receptor 2 (HER2) score were examined before and after neoadjuvant treatment. Younger age and a significant decrease in ER expression were associated with better prognosis. Triple Negative (TN) and Her2-type breast cancers benefited most from neoadjuvant chemotherapy with higher frequency of pCR. HER2-type and TN BC are correlated with best response to NAC. A statistically significant correlation between radiological images and definitive histological examination was not observed.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally advanced tumors (LABC) that aims at achieving a complete pathological response (pCR). Studies have been conducted to evaluate and identify te concordance between radiological, histopathological and biological variables of BC and final response to therapy, verified by definitive histological examination after surgery.
PATIENTS AND METHODS METHODS
Ninety-five BC patients were examined and subjected to NAC. Immunohistochemical markers including oestrogen-receptor (ER), progesterone-receptor (PR), Ki67 index, and human epidermal growth factor receptor 2 (HER2) score were examined before and after neoadjuvant treatment.
RESULTS RESULTS
Younger age and a significant decrease in ER expression were associated with better prognosis. Triple Negative (TN) and Her2-type breast cancers benefited most from neoadjuvant chemotherapy with higher frequency of pCR.
CONCLUSION CONCLUSIONS
HER2-type and TN BC are correlated with best response to NAC. A statistically significant correlation between radiological images and definitive histological examination was not observed.

Identifiants

pubmed: 31892577
pii: 40/1/281
doi: 10.21873/anticanres.13950
doi:

Substances chimiques

Ki-67 Antigen 0
Receptors, Estrogen 0
Receptors, Progesterone 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-286

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Oreste Claudio Buonomo (OC)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Andrea Grasso (A)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy andry993@tiscali.it.

Chiara Adriana Pistolese (CA)

Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Lucia Anemona (L)

Anatomic Pathology, Department of Experimental Medicine, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Ilaria Portarena (I)

Department of Oncology, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Rosaria Meucci (R)

Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Ljuba Morando (L)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Camilla Deiana (C)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Marco Materazzo (M)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Gianluca Vanni (G)

Breast Unit-Department of Surgical Science, Policlinico Tor Vergata (PTV) University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH